HPV Vaccination Recommendation Practices among Adolescent Health Care Providers in 5 Countries

Topazian HM 1 , Kundu D 1 , Peebles K 2 , Ramos S 3 , Morgan K 4 , Kim CJ 5 Show all authors , Richter KL 6 , Brewer NT 2 , Peris M 7 , Smith JS 8

Affiliations 

  • 1 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
  • 2 Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
  • 3 Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina
  • 4 Perdana University, Royal College of Surgeons in Ireland School of Medicine, Kuala Lumpur, Malaysia; Department of Psychology, Royal College of Surgeons in Ireland, Dublin, Ireland
  • 5 Department of Obstetrics and Gynecology, The Catholic University of Korea College of Medicine, St. Paul's Hospital, Seoul, Korea
  • 6 Department of Medical Virology, University of Pretoria, National Health Laboratory Service, Pretoria, South Africa
  • 7 Cancer Epidemiology Research Programme, Institut Català d'Oncologia, Barcelona, Spain
  • 8 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: [email protected]
J Pediatr Adolesc Gynecol, 2018 Dec;31(6):575-582.e2.
PMID: 30017958 DOI: 10.1016/j.jpag.2018.06.010

Abstract

STUDY OBJECTIVE: To assess adolescent health care providers' recommendations for, and attitudes towards human papillomavirus (HPV) vaccination in 5 countries.

DESIGN: In-depth interviews of adolescent health care providers, 2013-2014.

SETTING: Five countries where HPV vaccination is at various stages of implementation into national programs: Argentina, Malaysia, South Africa, South Korea, and Spain.

PARTICIPANTS: Adolescent health care providers (N = 151) who had administered or overseen provision of adolescent vaccinations (N = Argentina: 30, Malaysia: 30, South Africa: 31, South Korea: 30, Spain: 30).

MAIN OUTCOME MEASURES: Frequency of HPV vaccination recommendation, reasons providers do not always recommend the vaccine and facilitators to doing so, comfort level with recommending the vaccine, reasons for any discomfort, and positive and negative aspects of HPV vaccination.

RESULTS: Over half of providers 82/151 (54%) recommend HPV vaccination always or most of the time (range: 20% in Malaysia to 90% in Argentina). Most providers 112/151 (74%) said they were comfortable recommending HPV vaccination, although South Korea was an outlier 10/30 (33%). Providers cited protection against cervical cancer 124/151 (83%) and genital warts 56/151 (37%) as benefits of HPV vaccination. When asked about the problems with HPV vaccination, providers mentioned high cost 75/151 (50% overall; range: 26% in South Africa to 77% in South Korea) and vaccination safety 28/151 (19%; range: 7% in South Africa to 33% in Spain). Free, low-cost, or publicly available vaccination 59/151 (39%), and additional data on vaccination safety 52/151 (34%) and efficacy 43/151 (28%) were the most commonly cited facilitators of health provider vaccination recommendation.

CONCLUSION: Interventions to increase HPV vaccination should consider a country's specific provider concerns, such as reducing cost and providing information on vaccination safety and efficacy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications